Table 2.
Baseline population features
| n | p | |
|---|---|---|
| Study arm | ||
| Control | 23 (54.8%) | |
| Treatment | 19 (45.2%) | |
| Median age | ||
| Control | 69 (IQR 65–76.2) | 0.23 |
| Treatment | 73 (IQR 66–78) | |
| Multiple metastatic sites | ||
| Control | 17 (73.9%) | 0.07 |
| Treatment | 9 (47.4%) | |
| Baseline ISUP pattern ≥ 3 | ||
| Control | 17 (73.9%) | 0.15 |
| Treatment | 10 (52.6%) | |
| Median PSA at mCRPC occurrence | ||
| Control | 2.55 (IQR 1.2–6.11) | 0.76 |
| Treatment | 2, 91 (IQR 1.6–6.6) | |
| Staging at mCRPC occurrence | ||
| Choline PET/CT | 30 (71.4%) | |
| Bone scan/CT | 1(2.4%) | |
| PSMA PET/CT | 11(26.2%) | |
mCRPC metastatic castration resistant prostate cancer, PET/CT positron emission tomography/computed tomography, PSMA prostate specific membrane antigen